Accuray Reports Fiscal 2019 First Quarter Financial Results

Date : 10/30/2018 @ 8:05PM
Source : PR Newswire (US)
Stock : Accuray Incorporated (ARAY)
Quote : 2.67  0.11 (4.30%) @ 7:51PM
Accuray share price Chart

Accuray Reports Fiscal 2019 First Quarter Financial Results

Accuray (NASDAQ:ARAY)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Accuray Charts.

SUNNYVALE, Calif., Oct. 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2019 ended September 30, 2018.

Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

Company Highlights

  • China Ministry of Health confirms Type A and B quota and licenses
  • Gross orders increased 10 percent year over year to $61.4 million
  • Revenue increased 5 percent year over year to $95.8 million
  • Implements cost savings initiative

"Our fiscal year is off to a good start with double digit gross order growth and revenue generation meeting our targets," said Joshua H. Levine, president and chief executive officer. "We are also encouraged by the potential benefits to Accuray from the China Ministry of Health's announcement yesterday of Type A and B quota and licenses. In addition, we've implemented a cost savings initiative designed to reduce our annual operating costs by approximately $15 million and provide us with a clear path to GAAP profitability, while preserving our ability to continue our product innovation objectives and drive improved sales growth going forward. These cost savings have enabled us to raise our adjusted EBITDA outlook for the current fiscal year."

Fiscal First Quarter Results

Gross orders totaled $61.4 million, an increase of 10 percent compared to $55.6 million for the prior fiscal year period. Backlog as of September 30, 2018 was $461.9 million.

Total revenue was $95.8 million, an increase of 5 percent compared to $91.0 million in the prior fiscal year first quarter. Product revenue totaled $41.5 million compared to $38.9 million in the prior fiscal year first quarter, while service revenue totaled $54.3 million compared to $52.0 million in the prior fiscal year first quarter. Product revenue increased 7 percent year over year driven by strong growth in sales of the Company's Radixact Systems. Service revenue grew 4 percent year over year driven by software upgrades sold through service contracts.

Total gross profit for the fiscal 2019 first quarter was $37.9 million, or 39.5 percent of sales, comprised of product gross margin of 40.9 percent and service gross margin of 38.5 percent. This compares to total gross profit of $38.1 million, or 41.9 percent of sales, comprised of product gross margin of 43.2 percent and service gross margin of 40.9 percent for the prior fiscal year first quarter.

Operating expenses were $42.6 million, an increase of 6 percent compared to $40.2 million in the prior fiscal year first quarter. The fiscal first quarter 2019 operating expenses included a one-time accounts receivable impairment charge of $3.7 million. Excluding the impact of this impairment charge, fiscal first quarter 2019 operating expenses were $38.9  million.

Net loss was $9.2 million, or $0.11 per share, compared to a net loss of $9.4 million, or $0.11 per share, for the prior fiscal year first quarter.

Adjusted EBITDA for the first quarter of fiscal 2019 was $4.0 million, excluding the impact of a one-time impairment charge, compared to $3.1 million in the prior fiscal year first quarter.

Cash, cash equivalents and short-term restricted cash were $70.5 million as of September 30, 2018, a decrease of $22.4 million from June 30, 2018.

Cost Savings Initiative

Accuray has implemented a cost saving initiative designed to reduce operating costs and provide a clear path to GAAP net income while still focusing on top line growth. The actions implemented do not impact management's fiscal 2019 outlook for gross order and revenue growth and has resulted in an increase in the adjusted EBITDA outlook for the fiscal year.

As a result of the initiative, Accuray expects to take a non-recurring charge of $1.5 million to $2 million in the second fiscal quarter of 2019. The company expects annualized cost savings of approximately $15 million compared to fiscal 2018, with the full benefit realized starting in the fourth quarter of fiscal 2019.

2019 Financial Guidance

The Company is reaffirming revenue guidance provided on August 16, 2018 and updating adjusted EBITDA guidance for fiscal year 2019 as follows: 

  • Revenue: Product revenue growth is expected to range between 4 and 8 percent and service revenue is expected to grow approximately 2 percent, resulting in total revenue of between $415.0 million to $425.0 million, which would represent 3 to 5 percent growth year over year;
  • Adjusted EBITDA: $23.0 million to $29.0 million representing growth of approximately 35 percent to 70 percent year over year. The adjusted guidance reflects the impact of restructuring and excludes the impact of a one-time accounts receivable impairment charge and the one-time charge related to the announced cost savings initiatives. This is adjusted from the previous range of $21.0 million to $27.0 million.

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first fiscal quarter as well as recent corporate developments. Conference call dial-in information is as follows: 

  • U.S. callers: (855) 867-4103
  • International callers: (262) 912-4764
  • Conference ID Number (U.S. and international): 3146329

Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, www.accuray.com. In addition, a taped replay of the conference call will be available beginning approximately two hours after the call's conclusion and available for seven days. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 3146329. An archived webcast will also be available at Accuray's website.

Use of Non-GAAP Financial Measures

Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA").  Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results.  A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives.  The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding orders, revenue, and adjusted EBITDA; expectations related to GAAP net income profitability and sales growth; expectations regarding the company's product portfolio and future product enhancements and releases, including the impact of new products and releases on order growth; expectations regarding regulatory approvals, including the impact of such approvals on order growth; and the company's leadership position in radiation oncology innovation and technologies.  These forward-looking statements involve risks and uncertainties.  If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; risks and uncertainties related to the China Class A and B license announcement; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 24, 2018 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events.  The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Todd Kehrli


Beth Kaplan

Investor Relations, EVC Group


Public Relations Director, Accuray

+1 (310) 625-4462


+1 (408) 789-4426

tkehrli@evcgroup.com


bkaplan@accuray.com

Financial Tables to Follow

Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)



Three Months Ended

September 30,


2018


2017

Gross Orders

$

61,414


$

55,647

Net Orders


24,911



51,038

Order Backlog


461,876



464,968

Net revenue:






Products

$

41,517


$

38,916

Services


54,312



52,034

Total net revenue


95,829



90,950

Cost of revenue:






Cost of products


24,524



22,102

Cost of services


33,426



30,742

Total cost of revenue


57,950



52,844

Gross profit


37,879



38,106

Operating expenses:






Research and development


13,889



14,093

Selling and marketing


13,036



14,757

General and administrative


15,642



11,308

Total operating expenses


42,567



40,158

Loss from operations


(4,688)



(2,052)

Other expense, net


(3,983)



(6,571)

Loss before provision for income taxes


(8,671)



(8,623)

Provision for income taxes


535



759

Net loss

$

(9,206)


$

(9,382)

Net loss per share - basic and diluted

$

(0.11)


$

(0.11)

Weighted average common shares used in computing loss per share:






Basic and diluted


86,479



83,747

 

Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)



September 30,


June 30,


2018


2018

Assets






Current assets:






Cash and cash equivalents

$

68,545


$

83,083

Restricted cash


1,969



9,830

Accounts receivable, net


66,420



65,994

Inventories


117,684



108,540

Prepaid expenses and other current assets


17,075



15,569

Deferred cost of revenue


220



1,141

Total current assets


271,913



284,157

Property and equipment, net


23,126



23,698

Goodwill


57,767



57,855

Intangible assets, net


785



821

Other assets


15,540



12,196

Total assets

$

369,131


$

378,727

Liabilities and equity






Current liabilities:






Accounts payable

$

25,921


$

19,694

Accrued compensation


21,857



28,992

Other accrued liabilities


21,240



22,448

Customer advances


19,181



22,896

Deferred revenue


72,278



75,404

Total current liabilities


160,477



169,434

Long-term liabilities:






Long-term other liabilities


9,890



8,608

Deferred revenue


22,732



20,976

Long-term debt


128,926



131,077

Total liabilities


322,025



330,095

Equity:






Common stock


86



86

Additional paid-in capital


524,699



521,738

Accumulated other comprehensive income


698



1,093

Accumulated deficit


(478,377)



(474,285)

Total equity


47,106



48,632

Total liabilities and equity

$

369,131


$

378,727

 

Accuray Incorporated

Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)



Three Months Ended

September 30,


2018


2017

GAAP net loss

$

(9,206)


$

(9,382)

Amortization of intangibles


36



36

Depreciation (a)


2,093



2,478

Stock-based compensation


3,212



2,432

Interest expense, net (b)


3,592



6,820

Impairment charge (c)


3,707



-

Provision for income taxes


535



759

Adjusted EBITDA

$

3,969


$

3,143

________________________________

(a)

consists of depreciation, primarily on property and equipment.

(b)

consists primarily of interest income from available-for-sale securities, interest expense associated with our outstanding debt and non-cash loss on extinguishment of debt.

(c)

consists of a one-time accounts receivable impairment charge related to one customer

 

Accuray Incorporated

Forward-Looking Guidance

Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)




Twelve Months Ending

June 30, 2019



From


To

GAAP net loss


$

(23,000)


$

(17,000)

Depreciation and amortization (a)



10,100



10,100

Stock-based compensation



13,000



13,000

Impairment charge (b)



3,700



3,700

Cost savings initiative (c)



2,000



2,000

Interest expense, net (d)



15,100



15,100

Provision for income taxes



2,100



2,100

Adjusted EBITDA


$

23,000


$

29,000

________________________________

(a)

consists of depreciation, primarily on property and equipment as well as amortization of intangibles.

(b)

consists of a one-time accounts receivable impairment charge related to one customer recorded in the first quarter of 2019.

(c)

consists of costs associated with a staff reduction expected to be recorded in the second quarter of 2019.

(d)

consists primarily of interest expense associated with our outstanding debt.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-reports-fiscal-2019-first-quarter-financial-results-300740643.html

SOURCE Accuray Incorporated

Copyright 2018 PR Newswire

Latest ARAY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191018 19:07:43